Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Probiotics and Inflammatory Diseases
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Probiotics and Inflammatory Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: closed (25 April 2023) | Viewed by 1731

Special Issue Editors

Prof. Dr. Yunhe Fu

E-Mail Website
Guest Editor
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun 130062, China
Interests: intestine flora; rumen microbiome; pathogens
Special Issues, Collections and Topics in MDPI journals
Dr. Xiaoyu Hu

E-Mail Website
Guest Editor
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun 130062, China
Interests: gut microbiota; immunity; inflamamtion

Special Issue Information

Dear Colleagues,

With the advent of the post-antibiotic era, the role of probiotics in disease prevention and control has attracted more and more attention from clinical and scientific researchers. Probiotics have anti-inflammatory, antioxidant, anti-cancer, fat degradation, regulation of flora homeostasis and cellular and humoral immunity, and regulation of host organ immune function by bacteria directly or through the migration of metabolites to distal organs outside the intestine. Inflammatory diseases are important factors affecting animal and human health, and the application of probiotics in the prevention and treatment of inflammatory diseases will play an important role in promoting agricultural production and human social progress. This Special Issue, entitled “Probiotics and Inflammatory Diseases”, intends to present the correlation and mechanism between probiotics and inflammatory diseases and to identify new probiotics. Therefore, we cordially invite authors to contribute original research articles and reviews.

Prof. Dr. Yunhe Fu
Dr. Xiaoyu Hu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • probiotics
  • anti-inflammatory
  • antioxidant
  • gut microbiota
  • inflammatory disease
  • health-promoting

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 3252 KiB  
Article
VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC
by Shea F. Grenier, Mohammad W. Khan, Katherine A. Reil, Savannah Sawaged, Shingo Tsuji, Matthew J. Giacalone, Mengxi Tian and Kathleen L. McGuire
Int. J. Mol. Sci. 2023, 24(12), 9993; https://doi.org/10.3390/ijms24129993 - 10 Jun 2023
Cited by 2 | Viewed by 1456
Abstract
Colorectal cancer (CRC) remains the third most common form of cancer and, despite its reduced mortality, results in over 50,000 deaths annually, highlighting the need for novel therapeutic approaches. VAX014 is a novel clinical-stage, oncolytic bacterial minicell-based therapy shown to elicit protective antitumor [...] Read more.
Colorectal cancer (CRC) remains the third most common form of cancer and, despite its reduced mortality, results in over 50,000 deaths annually, highlighting the need for novel therapeutic approaches. VAX014 is a novel clinical-stage, oncolytic bacterial minicell-based therapy shown to elicit protective antitumor immune responses in cancer, but it has not been fully evaluated in CRC. Here, VAX014 was demonstrated to induce oncolysis in CRC cell lines in vitro and was evaluated in vivo, both as a prophylactic (before spontaneous development of adenomatous polyps) and as a neoadjuvant treatment using the Fabp-CreXApcfl468 preclinical animal model of colon cancer. As a prophylactic, VAX014 significantly reduced the size and number of adenomas without inducing long term changes in the gene expression of inflammatory, T helper 1 antitumor, and immunosuppression markers. In the presence of adenomas, a neoadjuvant VAX014 treatment reduced the number of tumors, induced the gene expression of antitumor TH1 immune markers in adenomas, and promoted the expansion of the probiotic bacterium Akkermansia muciniphila. The neoadjuvant VAX014 treatment was associated with decreased Ki67 proliferation in vivo, suggesting that VAX014 inhibits adenoma development through both oncolytic and immunotherapeutic effects. Combined, these data support the potential of VAX014 treatment in CRC and “at risk” polyp-bearing or early adenocarcinoma populations. Full article
(This article belongs to the Special Issue Probiotics and Inflammatory Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop